Oncology

Sofie Biosciences begins late-stage trials for a novel PET scan targeting aggressive gastrointestinal cancers, a breakthrough that could redefine detection.

Greenwich LifeSciences execs extend their stock lock-up to 6 years, signaling massive confidence in their breast cancer drug showing an 80% recurrence drop.

Adlai Nortye licenses its promising pan-RAS cancer inhibitor to ASK Pharm for Greater China in a deal valued at up to $230 million.

For the 13th consecutive year, Karmanos Cancer Institute is named a top US hospital, a distinction driven by patient safety and women's care preferences.

With backing from AstraZeneca and Pfizer, Beijing’s Syneron Bio is using its AI-driven platform to develop novel drugs for cancer and chronic illness.

In a fierce biotech talent war, Senti Bio's new equity grant for a key hire signals a strategic push for its gene therapy pipeline amid market volatility.

For the first time, Medicare and Medicaid will cover CBD products for senior cancer patients, a landmark decision with massive implications for patients and markets.

A new FDA approval for an EGFR-mutated lung cancer therapy cuts treatment from hours to minutes, offering new hope and convenience for thousands of patients.

The neuro-focused biotech just acquired a late-stage cancer drug, securing massive funding. Is this a brilliant diversification or a high-stakes gamble?

Molecular Partners readies for a pivotal presentation at the J.P. Morgan conference, showcasing its next-gen DARPin therapeutics for hard-to-treat cancers.

A Utah biotech reports promising results for a novel mRNA therapy that makes cancer cells look like measles, setting the stage for crucial animal trials.

With FDA & EMA alignment, atebimetinib heads to a Phase 3 trial, offering new hope against deadly pancreatic cancer based on promising early survival data.

A Phase 1 trial for Moleculin's WP1066 shows encouraging safety and anti-tumor activity for children with deadly brain tumors like DIPG.

NorthStar Medical Radioisotopes will showcase its revolutionary cancer-fighting isotopes, Ac-225 and Cu-67, at the prestigious J.P. Morgan conference.

New data reveals a novel therapy shrinks tumors in salivary gland cancer, offering hope where few options exist and validating a new oncology platform.

Armed with breakthrough data on an AI-designed therapy that penetrates the brain, Rakovina Therapeutics heads to JPM Week to court major partners.

Following a failed takeover bid, vaccine maker Bavarian Nordic appoints Heidi Hunter as Vice Chair, signaling a strategic pivot in its top leadership.

Pfizer projects lower 2026 earnings as COVID sales wane and patents expire, shifting focus to a multi-billion dollar R&D push for future growth.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

IO Biotech’s cancer vaccine posts impressive 5-year survival data, but a narrow miss in its pivotal trial creates an uncertain path in a competitive market.